Synergy Groups Medical — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$1,981,589	2
2024	Research	$1,166,852	25
2023	Research	$124,286	19

Breakdown

Who paid Research payments · program years 2023–2025

Amgen Inc. $2,988,169 3 payments
Taro Pharmaceuticals USA, Inc. $123,738 14 payments
Sun Pharmaceutical Industries Inc. $123,276 18 payments
Pfizer Inc. $35,996 5 payments
Bausch Health US, LLC $1,000 1 payment
Dermavant Sciences, Inc. $548 5 payments

Studies the money was for Research payments · program years 2023–2025

A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $1,981,484 1 payment
P4 Uncontrolled Gout FORWARD II $1,006,580 1 payment
RXLC 2118 $247,014 32 payments
An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $35,996 5 payments
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) $1,000 1 payment
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children With Adults $548 5 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity $105 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.